Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: a meta-analysis - Takeaways - MDSpire

Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: a meta-analysis

  • By

  • Giuseppe Panuccio

  • Nicole Carabetta

  • Martina Sportelli

  • Giuseppe Tartaglione

  • Kambis Mashayekhi

  • Emmanouil S. Brilakis

  • David M. Leistner

  • Sabato Sorrentino

  • Youssef Abdelwahed

  • Ulf Landmesser

  • Salvatore De Rosa

  • Daniele Torella

  • May 18, 2026

  • 0 min

Share

  • 1

    Percutaneous coronary intervention with drug-coated balloons offers a stent-free alternative for treating coronary artery disease.

  • 2

    Current guidelines recommend at least 6 months of dual antiplatelet therapy after drug-eluting stent implantation.

  • 3

    The optimal duration of dual antiplatelet therapy after drug-coated balloon angioplasty remains poorly defined.

  • 4

    This meta-analysis aims to evaluate the association between dual antiplatelet therapy duration and clinical outcomes after drug-coated balloon procedures.

  • 5

    Subgroup analyses will explore the impact of different DAPT regimens and lesion settings on bleeding and ischemic events.

Original Source(s)

Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: a meta-analysis

  • by Giuseppe Panuccio, Nicole Carabetta, Martina Sportelli, Giuseppe Tartaglione, Kambis Mashayekhi, Emmanouil S. Brilakis, David M. Leistner, Sabato Sorrentino, Youssef Abdelwahed, Ulf Landmesser, Salvatore De Rosa, Daniele Torella

  • May 18, 2026

Related Content

A review of the pathogenic mechanism and clinical management progress of in-stent calcification restenosis

Effect of stress-induced hyperglycaemia on clinical outcome in paitients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy